These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30578753)

  • 1. Syndecan-1 as an independent risk factor for the incidence of adverse cardiovascular events in patients having stage C and D heart failure with non-ischemic dilated cardiomyopathy.
    Liu W; Wang Y; Zheng J; Song D; Zheng S; Ren L; Wang Y; Yao Y; Wang Y; Liu Y; Bai R; Dong J; Liu T
    Clin Chim Acta; 2019 Mar; 490():63-68. PubMed ID: 30578753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrosis marker syndecan-1 and outcome in patients with heart failure with reduced and preserved ejection fraction.
    Tromp J; van der Pol A; Klip IT; de Boer RA; Jaarsma T; van Gilst WH; Voors AA; van Veldhuisen DJ; van der Meer P
    Circ Heart Fail; 2014 May; 7(3):457-62. PubMed ID: 24647119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heart failure biomarkers in patients with dilated cardiomyopathy.
    Bielecka-Dabrowa A; von Haehling S; Aronow WS; Ahmed MI; Rysz J; Banach M
    Int J Cardiol; 2013 Oct; 168(3):2404-10. PubMed ID: 23416015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of right atrial strain derived from cardiovascular magnetic resonance in non-ischemic dilated cardiomyopathy.
    Li Y; Guo J; Li W; Xu Y; Wan K; Xu Z; Zhu Y; Han Y; Sun J; Chen Y
    J Cardiovasc Magn Reson; 2022 Nov; 24(1):54. PubMed ID: 36352424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Objective criteria for septal fibrosis in non-ischemic dilated cardiomyopathy: validation for the prediction of future cardiovascular events.
    Mikami Y; Cornhill A; Heydari B; Joncas SX; Almehmadi F; Zahrani M; Bokhari M; Stirrat J; Yee R; Merchant N; Lydell CP; Howarth AG; White JA
    J Cardiovasc Magn Reson; 2016 Nov; 18(1):82. PubMed ID: 27839514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Cardiac T-Cadherin in the Indicating Heart Failure Severity of Patients with Non-Ischemic Dilated Cardiomyopathy.
    Baltrūnienė V; Rinkūnaitė I; Bogomolovas J; Bironaitė D; Kažukauskienė I; Šimoliūnas E; Ručinskas K; Puronaitė R; Bukelskienė V; Grabauskienė AV
    Medicina (Kaunas); 2020 Jan; 56(1):. PubMed ID: 31936691
    [No Abstract]   [Full Text] [Related]  

  • 7. T1-Mapping and Outcome in Nonischemic Cardiomyopathy: All-Cause Mortality and Heart Failure.
    Puntmann VO; Carr-White G; Jabbour A; Yu CY; Gebker R; Kelle S; Hinojar R; Doltra A; Varma N; Child N; Rogers T; Suna G; Arroyo Ucar E; Goodman B; Khan S; Dabir D; Herrmann E; Zeiher AM; Nagel E;
    JACC Cardiovasc Imaging; 2016 Jan; 9(1):40-50. PubMed ID: 26762873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of high sensitivity troponin T concentration in chronic stable patients with heart failure: Ischemic heart failure versus non-ischemic dilated cardiomyopathy.
    Bakal RB; Hatipoglu S; Kahveci G; Omaygenc MO; Unkun T; Akgun T; Sahin M; Elveran A; Ozveren O; Ozdemir N
    Cardiol J; 2014; 21(1):67-75. PubMed ID: 23799554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of blood pressure response plus gadolinium enhancement in dilated cardiomyopathy.
    Tateishi E; Noguchi T; Goto Y; Morita Y; Ishibashi-Ueda H; Yamada N; Kanzaki H; Nishimura K; Miyamoto Y; Anzai T; Ogawa H; Yasuda S
    Heart; 2015 May; 101(10):774-80. PubMed ID: 25761994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of myocardial strain and late gadolinium enhancement on cardiovascular magnetic resonance imaging in patients with idiopathic dilated cardiomyopathy with moderate to severely reduced ejection fraction.
    Pi SH; Kim SM; Choi JO; Kim EK; Chang SA; Choe YH; Lee SC; Jeon ES
    J Cardiovasc Magn Reson; 2018 Jun; 20(1):36. PubMed ID: 29898740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic differences in long-standing vs. recent-onset dilated cardiomyopathy.
    Silverdal J; Sjöland H; Pivodic A; Dahlström U; Fu M; Bollano E
    ESC Heart Fail; 2022 Apr; 9(2):1294-1303. PubMed ID: 35132793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential outcome of cardiac resynchronization therapy in ischemic cardiomyopathy and idiopathic dilated cardiomyopathy.
    McLeod CJ; Shen WK; Rea RF; Friedman PA; Hayes DL; Wokhlu A; Webster TL; Wiste HJ; Hodge DO; Bradley DJ; Hammill SC; Packer DL; Cha YM
    Heart Rhythm; 2011 Mar; 8(3):377-82. PubMed ID: 21070886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of dyslipidaemia in patients with heart failure of unexplained aetiology.
    Skwarek M; Bilińska ZT; Mazurkiewicz Ł; Grzybowski J; Kruk M; Kurjata P; Piotrowski W; Ruzyłło W
    Kardiol Pol; 2008 May; 66(5):515-22, discussion 523-4. PubMed ID: 18537059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of pulmonary hypertension in ambulatory patients with non-ischemic dilated cardiomyopathy.
    Hirashiki A; Kondo T; Adachi S; Nakano Y; Shimazu S; Shimizu S; Morimoto R; Okumura T; Murohara T
    Circ J; 2014; 78(5):1245-53. PubMed ID: 24621657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy.
    Rossi A; Dini FL; Faggiano P; Agricola E; Cicoira M; Frattini S; Simioniuc A; Gullace M; Ghio S; Enriquez-Sarano M; Temporelli PL
    Heart; 2011 Oct; 97(20):1675-80. PubMed ID: 21807656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heart rate turbulence as a predictor of cardiac mortality and arrhythmic events in patients with dilated cardiomyopathy: a prospective study.
    Miwa Y; Ikeda T; Sakaki K; Miyakoshi M; Ishiguro H; Tsukada T; Abe A; Mera H; Yusu S; Yoshino H
    J Cardiovasc Electrophysiol; 2009 Jul; 20(7):788-95. PubMed ID: 19298569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural history of dilated cardiomyopathy: from asymptomatic left ventricular dysfunction to heart failure--a subgroup analysis from the Trieste Cardiomyopathy Registry.
    Aleksova A; Sabbadini G; Merlo M; Pinamonti B; Barbati G; Zecchin M; Bussani R; Silvestri F; Iorio AM; Stolfo D; Dal Ferro M; Dragos AM; Meringolo G; Pyxaras S; Lo Giudice F; Perkan A; di Lenarda A; Sinagra G
    J Cardiovasc Med (Hagerstown); 2009 Sep; 10(9):699-705. PubMed ID: 19474760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Six-Minute Walk Test as a Predictor for Outcome in Children with Dilated Cardiomyopathy and Chronic Stable Heart Failure.
    den Boer SL; Flipse DH; van der Meulen MH; Backx AP; du Marchie Sarvaas GJ; Ten Harkel AD; van Iperen GG; Rammeloo LA; Tanke RB; Helbing WA; Takken T; Dalinghaus M
    Pediatr Cardiol; 2017 Mar; 38(3):465-471. PubMed ID: 27909753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of left atrial volume in patients with dilated cardiomyopathy.
    Ferreira F; Galrinho A; Soares R; Branco L; Abreu J; Feliciano J; Papoila AL; Virella D; Leal A; Cruz Ferreira R
    Rev Port Cardiol; 2013 Nov; 32(11):865-72. PubMed ID: 24119867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silent cerebral infarction in chronic heart failure: ischemic and nonischemic dilated cardiomyopathy.
    Kozdag G; Ciftci E; Ural D; Sahin T; Selekler M; Agacdiken A; Demirci A; Komsuoglu S; Komsuoglu B
    Vasc Health Risk Manag; 2008; 4(2):463-9. PubMed ID: 18561522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.